How COVID-19 interacts with interstitial lung disease
Copyright ©ERS 2022..
The global pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has had far-reaching impacts on patients with interstitial lung disease (ILD), from diagnosis to management. In addition, after infection, persistent parenchymal change is associated with ongoing symptoms and functional impairment even in patients without pre-existing lung disease. The challenge of investigating and treating these patients has often fallen to ILD physicians. This review therefore seeks to explore the relationship between COVID-19 and the interstitium, as well as the model of care for patients with pre-existing ILD and those patients with persistent disease following recovery from their initial infection.
Educational aims: To understand the impact of the COVID-19 pandemic on patients with existing interstitial lung disease.To explore the development of interstitial lung disease after COVID-19 infection.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2022 |
---|---|
Erschienen: |
2022 |
Enthalten in: |
Zur Gesamtaufnahme - volume:18 |
---|---|
Enthalten in: |
Breathe (Sheffield, England) - 18(2022), 1 vom: 14. März, Seite 210158 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Myall, Katherine J [VerfasserIn] |
---|
Links: |
---|
Themen: |
---|
Anmerkungen: |
Date Revised 16.07.2022 published: Print-Electronic Citation Status PubMed-not-MEDLINE |
---|
doi: |
10.1183/20734735.0158-2021 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM338147810 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM338147810 | ||
003 | DE-627 | ||
005 | 20231226000022.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231226s2022 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1183/20734735.0158-2021 |2 doi | |
028 | 5 | 2 | |a pubmed24n1127.xml |
035 | |a (DE-627)NLM338147810 | ||
035 | |a (NLM)35284020 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Myall, Katherine J |e verfasserin |4 aut | |
245 | 1 | 0 | |a How COVID-19 interacts with interstitial lung disease |
264 | 1 | |c 2022 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Revised 16.07.2022 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status PubMed-not-MEDLINE | ||
520 | |a Copyright ©ERS 2022. | ||
520 | |a The global pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has had far-reaching impacts on patients with interstitial lung disease (ILD), from diagnosis to management. In addition, after infection, persistent parenchymal change is associated with ongoing symptoms and functional impairment even in patients without pre-existing lung disease. The challenge of investigating and treating these patients has often fallen to ILD physicians. This review therefore seeks to explore the relationship between COVID-19 and the interstitium, as well as the model of care for patients with pre-existing ILD and those patients with persistent disease following recovery from their initial infection | ||
520 | |a Educational aims: To understand the impact of the COVID-19 pandemic on patients with existing interstitial lung disease.To explore the development of interstitial lung disease after COVID-19 infection | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Review | |
700 | 1 | |a Martinovic, Jennifer L |e verfasserin |4 aut | |
700 | 1 | |a West, Alex |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Breathe (Sheffield, England) |d 2014 |g 18(2022), 1 vom: 14. März, Seite 210158 |w (DE-627)NLM25214855X |x 1810-6838 |7 nnns |
773 | 1 | 8 | |g volume:18 |g year:2022 |g number:1 |g day:14 |g month:03 |g pages:210158 |
856 | 4 | 0 | |u http://dx.doi.org/10.1183/20734735.0158-2021 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 18 |j 2022 |e 1 |b 14 |c 03 |h 210158 |